Get the Stockscreener App
0.22
10.57%
-0.026
After Hours:
.22
Palatin Technologies Inc. stock is traded at $0.22, with a volume of 12.99M.
It is down -10.57% in the last 24 hours and down -72.84% over the past month.
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The company's principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its drug development programs also include melanocortin receptor system program, such as PL-8177, a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, a preclinical development candidate for treating ocular inflammation, as well as melanocortin receptor 4 peptides and orally-active small molecules to treat genetic metabolic and obesity disorders. In addition, the company develops natriuretic peptide receptor systems comprising PL3994, a natriuretic peptide receptor-A agonist, which has completed Phase I clinical study for the treatment of cardiovascular indications; and PL-5028, a dual natriuretic peptide receptor A and C agonist that is in preclinical development for cardiovascular diseases, such as reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.
See More
Previous Close:
$0.246
Open:
$0.252
24h Volume:
12.99M
Relative Volume:
6.13
Market Cap:
$4.95M
Revenue:
$7.10M
Net Income/Loss:
$-31.59M
P/E Ratio:
-0.0843
EPS:
-2.61
Net Cash Flow:
$-26.75M
1W Performance:
-47.90%
1M Performance:
-72.84%
6M Performance:
-78.00%
1Y Performance:
-88.42%
1-Day Range:
$0.2131
$0.252
1-Week Range:
$0.1605
$0.3111
52-Week Range:
$0.1605
$2.48
Palatin Technologies Inc. Stock (PTN) Company Profile
Name
Palatin Technologies Inc.
Sector
Industry
Phone
609-495-2200
Address
Cedar Brook Corporate Center, 4B Cedar Brook Drive, Cranbury, NJ
Compare PTN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTN
Palatin Technologies Inc.
|
0.22 | 4.95M | 7.10M | -31.59M | -26.75M | -2.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Palatin Technologies Inc. Stock (PTN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-15 | Reiterated | Canaccord Genuity | Buy |
| Jan-12-15 | Reiterated | ROTH Capital | Buy |
| May-23-12 | Initiated | Noble Financial | Buy |
| Jan-23-07 | Initiated | Next Generation | Buy |
Palatin Technologies Inc. Stock (PTN) Latest News
Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide - The Malaysian Reserve
Dry Eye Disease Market Growth Projections 2024-2034: DelveInsight Analysis | Palatin Technologies, Novaliq, mc2 therapeutics - The Globe and Mail
Palatin (PTN) Reports Positive Phase 2 Study Results for Obesity Treatment | PTN Stock News - GuruFocus
Palatin’s obesity study shows promise in appetite control - Investing.com
Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide | PTN Stock News - GuruFocus
Palatin’s obesity study shows promise in appetite control By Investing.com - Investing.com UK
Breakthrough Obesity Treatment Shows 71% Appetite Control, Blocks Post-Treatment Weight Rebound - Stock Titan
What Analysts Think About Palatin Technologies Inc (AMEX: PTN)’s Potential Raise - stocksregister.com
Palatin Appeals NYSE American Notice of Delisting - Kilgore News Herald
Palatin Technologies (PTN) Appeals NYSE Delisting Decision | PTN Stock News - GuruFocus
Palatin Appeals NYSE American Notice of Delisting | PTN Stock Ne - GuruFocus
Palatin Appeals NYSE Delisting, Pursues Financing And Partnerships To Regain Compliance - Nasdaq
Palatin contests NYSE American delisting notice By Investing.com - Investing.com South Africa
Palatin Appeals NYSE American Notice of Delisting | PTN Stock News - GuruFocus
Palatin contests NYSE American delisting notice - Investing.com
Palatin Appeals NYSE American Notice Of Delisting - marketscreener.com
Palatin Launches Bold Defense Against NYSE Delisting: Multi-Strategy Rescue Plan Revealed - Stock Titan
Stock Slump: Eyewear Innovator And Tech Firms Face Market Hits - Finimize
Palatin Technologies (PTN) Faces NYSE American Delisting Proceedings - GuruFocus
Palatin (PTN) Faces Delisting Proceedings from NYSE American | P - GuruFocus
Palatin to Present Positive Phase 2b Data for Melanocortin Agoni - GuruFocus
Palatin Technologies faces potential NYSE American delisting By Investing.com - Investing.com Canada
Palatin reports promising kidney disease treatment results By Investing.com - Investing.com South Africa
Palatin Technologies shares fall as it receives NYSE American delisting notice - MSN
Palatin Technologies faces potential NYSE American delisting - Investing.com Australia
Palatin Technologies, Inc. Announces Receipt Of NYSE American Notice Of Delisting And Intention To Appeal - MarketScreener
NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN) - Business Wire
Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal - PR Newswire
Palatin reports promising kidney disease treatment results - Investing.com Australia
Palatin Technologies Reports Positive Data From Phase 2b BREAKOUT Study - Nasdaq
Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting - Kilgore News Herald
Indo-Asian News Service - Indo-Asian News Service (IANS)
Palatin Technologies stock hits 52-week low at $0.45 - Investing.com
Palatin Technologies stock hits 52-week low at $0.45 By Investing.com - Investing.com India
Palatin touts Phase II obesity study results - The Pharma Letter
Palatin study shows weight loss with new drug combo By Investing.com - Investing.com Canada
Palatin Technologies’ UC Treatment Shows Remarkable 78% Clinical Response Rate in Phase 2 Topline Data – Potential Game-Changer for Millions Suffering from Ulcerative Colitis (NYSE: PTN) - Barchart.com
Palatin Technologies' Obesity Drug Co-Administered With Eli Lilly's Blockbuster Drug Shows 4.4% Reduction In Weight - Benzinga
Palatin study shows weight loss with new drug combo - Investing.com
Breakthrough Obesity Treatment: New Drug Combo Achieves 4.4% Weight Loss in Clinical Trial - Stock Titan
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study - The Malaysian Reserve
Palatin reported promising results in trial for ulcerative colitis treatment - MSN
PTN stock touches 52-week low at $0.67 amid market challenges - Investing.com Australia
PTN stock touches 52-week low at $0.67 amid market challenges By Investing.com - Investing.com South Africa
Palatin’s UC therapy prompts clinical remission in a third of patients - Yahoo
Palatin Technologies' Ulcerative Colitis Drug Candidate Shows Positive Results in Phase 2 Study - MarketScreener
Palatin reported promising results in trial for ulcerative colitis treatment (PTN:NYSE) - Seeking Alpha
Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177 - The Malaysian Reserve
Palatin Technologies Touts Positive Results From Mid-Stage Study For Experimental Drug For Ulcerative Colitis, Halts Patients Enrollment Citing Strategic Focus - Benzinga
Palatin Technologies Inc. Stock (PTN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):